AMNEAL PHARMACEUTICALS INC (AMRX) Stock Analyst Ratings
USA - NASDAQ:AMRX - US03168L1052 - Common Stock
11.95 USD
+0.47 (+4.09%)
12 USD
+0.05 (+0.42%)
ChartMill assigns a Buy % Consensus number of 82% to AMRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.24. This target is 2.43% above the current price.
AMRX was analyzed by 10 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about AMRX.
In the previous month the buy percentage consensus was at a similar level.
AMRX was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-31 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-09-16 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-03 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-24 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2024-11-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-10-02 | Truist Securities | Maintains | Buy -> Buy |
| 2024-09-06 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-08-13 | Barclays | Maintains | Overweight -> Overweight |
| 2024-08-12 | Truist Securities | Maintains | Buy -> Buy |
| 2024-05-06 | Truist Securities | Reiterate | Buy -> Buy |
| 2024-05-06 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-03-21 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-03-04 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-01-29 | Barclays | Maintains | Overweight -> Overweight |
| 2023-11-08 | Truist Securities | Maintains | Buy -> Buy |
| 2023-09-06 | Truist Securities | Reiterate | Buy -> Buy |
| 2023-08-07 | Barclays | Maintains | Overweight -> Overweight |
| 2023-08-07 | Truist Securities | Maintains | Buy -> Buy |
| 2023-08-07 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-05-08 | Piper Sandler | Maintains | Overweight |
| 2023-03-29 | Truist Securities | Maintains | Buy |
| 2023-03-10 | Barclays | Maintains | Overweight |
| 2023-03-03 | BMO Capital | Maintains | Market Perform |
| 2023-03-03 | Goldman Sachs | Maintains | Buy |
| 2022-08-08 | Goldman Sachs | Maintains | Buy |
| 2022-05-12 | Goldman Sachs | Maintains | Buy |
| 2021-03-08 | Goldman Sachs | Upgrade | Sell -> Buy |
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What is the price target for AMRX stock?
10 analysts have analysed AMRX and the average price target is 12.24 USD. This implies a price increase of 2.43% is expected in the next year compared to the current price of 11.95.
What is the consensus rating for AMNEAL PHARMACEUTICALS INC (AMRX) stock?
The consensus rating for AMNEAL PHARMACEUTICALS INC (AMRX) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.